Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma
Status:
Active, not recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to establish whether adjuvant therapy with lenalidomide +
dexamethasone after radiotherapy can improve progression free survival in patients with high
risk solitary bone plasmacytoma compared with RT only.